Baird Medical Files Full Terms of $4.35M Convertible Note with 92% VWAP Discount Conversion
BDMD sits 18% above its 52-week low of $0.661.
Summary
Baird Medical filed the full terms of a $4.35 million senior secured convertible note with a 92% VWAP discount conversion feature, a pledge of its U.S. subsidiary, and a first-priority lien on U.S. assets — terms that heavily favor the investor.
Key Events · Financing and Capital Events · BDMD
-
Convertible Note Terms Disclosed
The company issued a senior 8% original issue discount convertible note with a principal amount of $4,347,826 for a $4,000,000 subscription amount. The note converts at the lower of $0.9842 (120% of the three-day VWAP before closing) or 92% of the lowest daily VWAP over the seven trading days before conversion (85% upon default).
-
Investor Identified
The investor is L1 Capital Global Opportunities Master Fund, a Cayman Islands exempted company. The investor has the obligation to lend an additional $3,680,000 within 180 days and up to $6 million more within 360 days, subject to conditions including a closing price above $1.00.
-
Secured by U.S. Assets and Subsidiary Equity
The note is secured by a first-priority perfected security interest in substantially all U.S. assets of the company and Baird Medical LLC, plus a pledge of all equity interests of Baird Med LLC. All subsidiaries except two excluded entities guarantee the note.
-
Pre-Delivery and Discount Shares
The company issued 1,500,000 Pre-Delivery Shares to facilitate conversions and 110,070 Discount Shares at $0.79 per share for the additional 2% original issue discount. The investor is subject to a 9.99% beneficial ownership limitation.
Analysis · BDMD · Industrial Applications And Services
The complete Securities Purchase Agreement for a $4.35 million senior secured convertible note has been filed, and the terms heavily favor the investor. Conversion occurs at the lower of $0.9842 or 92% of the lowest daily VWAP over the prior seven trading days — a structure that lets the investor convert at a discount to market and sell into any strength. The company also pledged its U.S. operating subsidiary's equity and granted a first-priority lien on substantially all U.S. assets, meaning the investor has a claim on the company's core assets ahead of other creditors. This comes just days after the company disclosed a going-concern assessment resolved only through a $2.0 million support letter from its CEO, and follows a $27.5 million annual loss with just $0.2 million in cash. The financing keeps the company alive but at the cost of severe potential dilution and a senior secured claim on its assets.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDMD was trading at $0.78 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $25M. The 52-week trading range was $0.66 to $3.70. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.